TransMedics Group Inc. (TMDX)
TransMedics Group, Inc. (TMDX) Q3 2024 Earnings Call Transcript
TransMedics Group, Inc. (NASDAQ:TMDX ) Q3 2024 Earnings Conference Call October 28, 2024 4:30 PM ET Company Participants Laine Morgan - Gilmartin Group, Investor Relations Waleed Hassanein - President and Chief Executive Officer Stephen Gordon - Chief Financial Officer Conference Call Participants Allen Gong - JPMorgan William Plovanic - Canaccord Joshua Jennings - TD Cowen Ryan Daniels - William Blair Matthew O'Brien - Piper Sandler Suraj Kalia - Oppenheimer & Company David Rescott - Baird Mike Matson - Needham & Company Operator Good afternoon and welcome to the TransMedics Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
TransMedics (TMDX) Q3 Earnings and Revenues Miss Estimates
TransMedics (TMDX) came out with quarterly earnings of $0.12 per share, missing the Zacks Consensus Estimate of $0.28 per share. This compares to loss of $0.12 per share a year ago.
TransMedics, F5 Lead Big After-Hours Earnings Winners, Losers
With earnings season in full swing, big winners and losers abound. TransMedics and F5 were notable movers Monday night.
Stay Ahead of the Game With TransMedics (TMDX) Q3 Earnings: Wall Street's Insights on Key Metrics
Evaluate the expected performance of TransMedics (TMDX) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Transplant Logistic Service Business Likely to Aid TMDX's Q3 Earnings
Expanding transplant logistic service business is likely to have driven TransMedics' third-quarter 2024 performance.
TransMedics (TMDX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
TransMedics (TMDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TransMedics Group: This Could Be One Of The Biggest Moats In A Decade
The company's unique FDA-approved multi-organ platform and proprietary aviation division enhance its competitive edge, reducing costs and improving surgical outcomes. While there are risks, including liquidity and potential competition, the long-term benefits and market position make TransMedics a compelling buy-and-hold investment. And most importantly, it is a product that could lead to a huge moat in the advancement of human medicine.
FMR LLC's Strategic Reduction in TransMedics Group Inc Shares
On September 30, 2024, FMR LLC (Trades, Portfolio) executed a significant transaction involving the sale of 2,281,896 shares of TransMedics Group Inc (TMDX, Financial), a leader in advanced organ transplant technology. This move reduced FMR LLC (Trades, Portfolio)'s holdings in the company by 50.82%, leaving them with a total of 2,208,308 shares.
Does TransMedics (TMDX) Have the Potential to Rally 26.49% as Wall Street Analysts Expect?
The mean of analysts' price targets for TransMedics (TMDX) points to a 26.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
TransMedics (TMDX) Moves 10.1% Higher: Will This Strength Last?
TransMedics (TMDX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
TransMedics: Wide Moat Player At A Lower Valuation Than Peers
TransMedics is revolutionizing organ transportation with its FDA-approved Organ Care System, improving organ functionality during transport. Significant investments in logistics, including owning aircraft, enhancing its moat, reducing graft dysfunction by 50% and improving donation effectiveness. The company has a strong competitive edge, evident in its 100%+ YoY sales growth and 10-12% net margins, yet trades at a lower EV/Sales multiple than peers.
Why Shares of TransMedics Stock Plunged This Week
TransMedics' one-year beta is ballooning, meaning the stock is becoming increasingly more volatile. Furthermore, a growing number of traders are betting against the stock.
